Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Bayer Japan Ethical Drug Sales Grow 4.2% in 2019
Bayer Yakuhin, the Japan pharma arm of Bayer AG, said on April 28 that its ethical drug sales in 2019 rose 4.2% over the previous year to 315.3 billion yen on an NHI price basis thanks to strong performances seen…
To read the full story
Related Article
- Bayer Yakuhin Sees 2021 Sales Skid 0.6% but Still Reach Target, Retains Spot in Top 10
April 15, 2022
- Bayer’s Japan Sales Sag 5%, but Targets Reached in 2020
April 19, 2021
- Bayer Japan Ethical Drug Sales Slip 1% in 2018
April 15, 2019
BUSINESS
- Eylea Biosimilar Shipment Restrictions to Be Lifted on June 5
May 27, 2026
- Bayer’s Low-Dose MRI Contrast Agent Ambelvist Debuts in Japan
May 27, 2026
- Eisai Eyes 1 Trillion yen in FY2028 Sales under 3-Year Plan
May 26, 2026
- Nippon Kayaku to Take Over AstraZeneca’s Zoladex in Japan
May 26, 2026
- Jardiance Triumphs in Six Promotion Channels in April: Intage
May 26, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…